Agile Therapeutics Announces Publication of Data On Low-Dose Investigational Contraceptive Patch

Agile Therapeutics, Inc.

today announced the publication of two manuscripts containing data from a Phase 3 clinical trial of Twirla® (AG200-15), an investigational, once-weekly contraceptive patch. Kaunitz A, Portman D, Westhoff C, Mishell D, Archer D, Foegh M. New Contraceptive Patch Wearability Assessed by Investigators and Participants in a Randomized, Phase 3 Study. Contraception 2014 DOI: http://dx.doi.org/10.1016/j.contraception.2014.11.013 Kaunitz A, Portman D, Westhoff C, Archer D, Mishell, D, Foegh M. Self-Reported and Verified Compliance in a Phase 3 Clinical Trial of a Novel Low-Dose Contraceptive Patch and Pill. Contraception 2014 DOI: http://dx.doi.org/10.1016/j.contraception.2014.11.011 Agile recently initiated an additional Phase 3 trial with Twirla, the SECURE study, which will provide further data on the safety, tolerability, and effectiveness of this low-dose contraceptive patch.